NCT04044430View on ClinicalTrials.gov

Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Metastatic Colon AdenocarcinomaMetastatic Colorectal AdenocarcinomaMetastatic Microsatellite Stable Colorectal CarcinomaMetastatic Rectal AdenocarcinomaStage III Colon CancerStage III Colorectal CancerStage III Rectal CancerStage IIIA Colon CancerStage IIIA Colorectal CancerStage IIIA Rectal CancerStage IIIB Colon CancerStage IIIB Colorectal CancerStage IIIB Rectal CancerStage IIIC Colon CancerStage IIIC Colorectal CancerStage IIIC Rectal CancerStage IV Colon CancerStage IV Colorectal CancerStage IV Rectal CancerStage IVA Colon CancerStage IVA Colorectal CancerStage IVA Rectal CancerStage IVB Colon CancerStage IVB Colorectal CancerStage IVB Rectal CancerStage IVC Colon CancerStage IVC Colorectal CancerStage IVC Rectal Cancer
Interventions
DRUG

Binimetinib

Given PO

DRUG

Encorafenib

Given PO

BIOLOGICAL

Nivolumab

Given IV

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (2)

94115

Kaiser Permanente Northern California, San Francisco

Univeristy of California, San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of California, San Francisco

OTHER